BioNano Genomics Inc vs Progressive Corp — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.20M), while Progressive Corp trades at $204.75 (market cap $131.91B). The key difference: Progressive Corp is far larger — about 9993.2× BioNano Genomics Inc's market cap, and Progressive Corp pays a 6.13% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | PGR | |
|---|---|---|
Market Cap | $13.20M | $131.91B |
Sector | Health | Financials |
52-Week High | $4.92 | $252.68 |
52-Week Low | $1.09 | $190.40 |
Enterprise Value | $15.81M | $140.14B |
Dividend Yield | — | 6.13% |
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Progressive (PGR) trades at $234.48, up 1.63% today, near its consensus price target of $240.89. The stock shows strong fundamentals with revenue growth from $49.6B in 2022 to $87.6B in 2025 and a net income margin of 12.93%. Technical indicators are bullish, with the price above key moving averages. Recent news highlights focus on Q2 2026 earnings expectations due July 15, 2026.
Outlook is positive given earnings growth and analyst buy ratings, but risks include potential earnings misses and competitive pressures. The stock offers value with a P/E of 11.93, below industry averages, supporting a bullish view for long-term investors despite near-term volatility.
Trailing returns across standard periods
Latest headlines on both assets
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →